Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- DTRM +7.8%, ASNA +5.8%, ARIS +4.5%, LMNR +4.2%, OESX +3.7%, KMG +2.3%, LAYN +0.8%
M&A news:
- DFT +15.5% (DFT will merge with Digital Realty (DLR) in an all-stock transaction), DLR +1.9%
- ADHD +12.4% (vague M&A chatter)
- DISH +2.4% (renewed AMZN M&A chatter circulates)
Other news:
- ONCS +7.1% (confirms being granted Orphan Drug Designation for pIL-12 for the treatment of unresectable metastatic melanoma )
- COLL +5.1% (following Opana ER news; also will present data on Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on June 11-12)
- LXRX +4.8% (announces positive top-line results from its Phase 3 inTandem3 study of sotagliflozin for the treatment of patients with type 1 diabetes on any background insulin therapyg)
- P +3.3% (SiriusXM (SIRI) to make a $480 mln strategic cash investment in Pandora)
- INO +3.3% (CEO featured on Thursday's Mad Money)
- IIVI +2.3% (is ramping up production of 18 W pump laser diodes for fiber lasers; will double production capacity by the end of this year)
- OHI +2% (appointed Craig R. Callen as Chairman)
- AGTC +2% (Applied Genetic Technologies to present topline safety data for dose escalation phase of its Ph 1/2 X-linked retinoschisis clinical trial at Macula Society Annual Meeting in Singapore on June 10 )
- AMD +1.6% (scontinued strength)
- AAL +0.5% (May Traffic)
Analyst comments:
- ZNGA +3.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NVDA +2.3% (target raised to $175 from $140 at Argus)
- CWH +2.1% (upgraded to Buy from Neutral at Goldman )
- C +0.7% (upgraded to Neutral from Sell at UBS )
- PYPL +0.7% (target raised to $62 from $52 at Citigroup)
- ADBE +0.6% ( target raised to $160 from $140 at BMO Capital Markets)